168 related articles for article (PubMed ID: 38195475)
1. Immune characteristics and clinical significance of peripheral blood lymphocytes in breast cancer.
Gao H; Ouyang D; Guan X; Xu J; Chen Q; Zeng L; Pang J; Zou Q; Qian K; Yi W
BMC Cancer; 2024 Jan; 24(1):50. PubMed ID: 38195475
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis.
Ma J; Li J; He N; Qian M; Lu Y; Wang X; Wu K
J Transl Med; 2023 Feb; 21(1):73. PubMed ID: 36737759
[TBL] [Abstract][Full Text] [Related]
3. Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.
Wesolowski R; Stiff A; Quiroga D; McQuinn C; Li Z; Nitta H; Savardekar H; Benner B; Ramaswamy B; Lustberg M; Layman RM; Macrae E; Kassem M; Williams N; Sardesai S; VanDeusen J; Stover D; Cherian M; Mace TA; Yu L; Duggan M; Carson WE
BMC Cancer; 2020 May; 20(1):445. PubMed ID: 32429929
[TBL] [Abstract][Full Text] [Related]
4. Frequencies of PD-1- and PD-L1- positive T CD3
Nowicka D; Grywalska E; Surdacka A; Grafka A; Roliński J
Microb Pathog; 2019 Jan; 126():85-91. PubMed ID: 30342909
[TBL] [Abstract][Full Text] [Related]
5. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival.
Schlotter CM; Tietze L; Vogt U; Heinsen CV; Hahn A
Horm Mol Biol Clin Investig; 2017 Sep; 32(2):. PubMed ID: 28937963
[TBL] [Abstract][Full Text] [Related]
6. Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.
Pelekanou V; Carvajal-Hausdorf DE; Altan M; Wasserman B; Carvajal-Hausdorf C; Wimberly H; Brown J; Lannin D; Pusztai L; Rimm DL
Breast Cancer Res; 2017 Aug; 19(1):91. PubMed ID: 28784153
[TBL] [Abstract][Full Text] [Related]
7. [Distribution and Clinical Significance of CTLA-4, PD-1 and PD-L1 in Peripheral Blood of Patients with Small Cell Lung Cancer].
Li H; Liu Y; Liu Y; Liu J; Zhao D; Wang Y; Cheng Y
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):755-760. PubMed ID: 29167005
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of regulatory T cells and T lymphocyte subsets in peripheral blood in neoadjuvant chemotherapy for breast cancer.
Mao XD; Chen SZ; Shen SQ; Liu KS
Am J Cancer Res; 2023; 13(7):3091-3099. PubMed ID: 37559980
[TBL] [Abstract][Full Text] [Related]
9. Peripheral blood lymphocytes subtypes as new predictors for neoadjuvant therapy efficacy in breast cancer.
Feng J; Yi J; Zouxu X; Li J; Xiong Z; Huang X; Zhong W; Huang W; Ye F; Wang X
Cancer Med; 2022 Aug; 11(15):2923-2933. PubMed ID: 35411609
[TBL] [Abstract][Full Text] [Related]
10. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS
Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 Acts as a Promising Immune Marker to Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.
Du Q; Che J; Jiang X; Li L; Luo X; Li Q
Clin Breast Cancer; 2020 Feb; 20(1):e99-e111. PubMed ID: 31521537
[TBL] [Abstract][Full Text] [Related]
12. The role and clinical significance of programmed cell death- ligand 1 expressed on CD19
Jia XY; Zhu QQ; Wang YY; Lu Y; Li ZJ; Li BQ; Tang J; Wang HT; Song CW; Xie CH; Chen LJ
Clin Immunol; 2019 Jan; 198():89-99. PubMed ID: 30502542
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells.
Tawfik O; Kimler BF; Karnik T; Shehata P
Hum Pathol; 2018 Oct; 80():170-178. PubMed ID: 29936058
[TBL] [Abstract][Full Text] [Related]
14. Peripheral blood lymphocytes differentiation patterns in responses / outcomes to immune checkpoint blockade therapies in non-small cell lung cancer: a retrospective study.
Du X; Wen S; Shi R; Xia J; Wang R; Zhang Y; Pan B; Wu X; Zhu W; Feng J; Wang X; Shen B
BMC Cancer; 2023 Jan; 23(1):83. PubMed ID: 36698098
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
16. The effect of PD-1/PD-L1 signaling axis on the interaction between CD19
Xie Z; Dai L; He H; Hong D; Tang H; Xu W; Chen Z; Wang H; Li B; Xie C; Wang Y
Adv Rheumatol; 2023 Oct; 63(1):51. PubMed ID: 37848996
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte subset expression and serum concentrations of PD-1/PD-L1 in sepsis - pilot study.
Wilson JK; Zhao Y; Singer M; Spencer J; Shankar-Hari M
Crit Care; 2018 Apr; 22(1):95. PubMed ID: 29661225
[TBL] [Abstract][Full Text] [Related]
18. [Effect of dendritic cells on immune function regulated by programmed cell death-1/programmed cell death-ligand 1 in sepsis].
Wang Z; Xie Z; Zhao Y; Bu T; Yu A; Wang S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Sep; 33(9):1032-1039. PubMed ID: 34839857
[TBL] [Abstract][Full Text] [Related]
19. Expression of PD-L1 in Early-Stage Invasive Breast Carcinoma and Its Relation to Tumor-Infiltrating Lymphocytes.
Amin NH; Abou-Bakr AA; Eissa S; Nassar HR; Eissa TS; Mohamed G
Asian Pac J Cancer Prev; 2022 Mar; 23(3):1091-1102. PubMed ID: 35345385
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Significance of Circulating CD28 Negative Suppressor T Cells and Memory B Cells in Patients with Breast Cancer.
Zahran AM; Shaltout AS; Fakhry H; Khallaf SM; Abdel Fattah ON; Temerik DF; Rayan A
Iran J Immunol; 2020 Jun; 17(2):95-110. PubMed ID: 32602464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
